世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

強度変調放射線治療市場：照射タイプ（光子、電子線、陽子線、炭素線）、用途（前立腺、肺、乳房）、エンドユーザー（病院、独立放射線治療センター）、地域別 - 2028年までの世界予測


Intensity-modulated Radiotherapy Market by Radiation Type (Photon,Electron Beam, Proton and Carbon-Ion Radiation) Application (Prostate, Lung, Breast), End Users ( Hospitals and Independent Radiotherapy centers), and Region - Global Forecasts to 2028

世界の強度変調放射線治療市場は、2023年の22億米ドルから2028年には28億米ドルに達し、予測期間中のCAGRは5.2％で成長すると予測されている。強度変調放射線治療市場（IMRT）の市場成長急増の予測は、説得力のあ... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2023年9月25日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		160 111 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の強度変調放射線治療市場は、2023年の22億米ドルから2028年には28億米ドルに達し、予測期間中のCAGRは5.2％で成長すると予測されている。強度変調放射線治療市場（IMRT）の市場成長急増の予測は、説得力のある利点の合流によって支えられている。特に、IMRTの「腫瘍の標的化において卓越した精度を達成する能力」は、健康な組織への付随的な損傷を軽減する能力と相まって、極めて重要な推進力となっている。さらに、世界的ながん罹患率の増加は、IMRTを最前線のソリューションと位置づける先進的な治療法に対する需要を増大させている。このような要因が重なることで、IMRT市場は堅調な拡大局面を迎えることになり、その結果、今後数年間のIMRT導入の展望が形作られることになる。

「2023～2027年の予測期間で最も高いCAGRを記録するのは脳腫瘍アプリケーション分野
用途に基づき、強度変調放射線治療市場は前立腺がん、肺がん、頭頸部がん、乳がん、消化器がん、婦人科がん、その他の用途に区分される。2022年に最も高い成長率を示すのは乳がんである。乳がんの増加は、加齢要因、BRCA1やBRCA2のような遺伝的要因、乳がん症例のごく一部に寄与する遺伝的遺伝子変異、ホルモン補充療法の使用が乳がんの発生率を増加させる潜在的要因のいくつかである。乳癌の発生率は増加しているように見えるかもしれないが、乳癌死亡率は早期発見と治療の進歩により減少している。IMRTにより、医師と患者は適切な放射線強度を用いて効率的に細胞を根絶することができる。

"強度変調放射線治療市場2022-2027年、病院セグメントが最大市場シェアを占める"
強度変調放射線治療市場の主なエンドユーザーは病院である。病院のエンドユーザーセグメントは、予測期間中、強度変調放射線治療市場で大きな市場シェアを占めると推定されている。病院は、1つの施設内で包括的な医療サービスを提供できることが特徴であり、強度変調放射線治療市場（IMRT）を受ける患者に独特の利便性を与える。この利便性は、多様な医療ニーズをひとつ屋根の下に集約することにより、患者が別々の場所で複数の予約を取る必要性を軽減することに由来する。このようなサービスの戦略的統合は、患者の治療を合理化するだけでなく、好ましい治療オプションとしてのIMRTの魅力を増大させる。その結果、利便性と包括的ケアのシームレスな連携が、病院内での強度変調放射線治療市場の発展と隆盛に大きく寄与している。
技術の進歩：病院は、強度変調放射線治療（IMRT）市場の統合を成功させるために不可欠な最先端のインフラと技術能力を頻繁に維持しており、必要なリソースをすぐに利用できるようにしている。この極めて重要な特性は、画像誘導放射線治療市場の発展と強化に明確に寄与している。

「予測期間中、アジア太平洋地域が大きな成長率を記録する
予測期間2023-2028年において、APAC地域は予測期間中に市場で著しい成長率を記録すると予想されている。アジア太平洋地域は、インド、中国、日本、オーストラリア、韓国、RoAPACで構成される。アジア太平洋（APAC）地域は、画像誘導放射線治療の市場成長率が大幅に上昇している。この成長にはいくつかの要因がある：
APAC諸国では人口動態が成熟しつつあり、治療に関連する副作用を最小限に抑えた効率的ながん治療法が求められている。強度変調放射線治療市場（IMRT）の精密さ主導の特性との共鳴は、市場展望を強化する上で極めて重要な役割を立証している。
APACの病院では多言語による患者治療が行われており、強度変調放射線治療市場（IMRT）のような先進治療へのアクセスが可能であることから、特に多様な患者の間で、この地域に独特の魅力がもたらされている。このような言語的包括性と最先端の医療介入の融合は、この地域が好まれている医療目的地としての望ましさを著しく高め、その結果、医療市場における競争力を強化し、IMRTの隆盛を後押ししている。

本レポートの主な参加企業の内訳は以下の通りである：
- 企業タイプ別企業タイプ別：ティア1-40％、ティア2-30％、ティア3-30
- 役職別Cレベル-27％、ディレクターレベル-18％、その他-55
- 地域別北米-50%、欧州-20%、アジア太平洋地域-15%、中南米-10%、中東・アフリカ-5

同市場における有力企業は、Varian Medical Systems, Inc.、Elekta（スウェーデン）、Accuray Incorporated（米国）、日立製作所（日本）などである。

調査範囲

- この調査レポートは、強度変調放射線治療市場を放射線の種類、用途、エンドユーザー、地域に基づいて調査しています。
- 市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。
- 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。
- 微小市場の成長動向、展望、世界の強度変調放射線治療市場への貢献に関して調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の主な利点

本レポートは、包括的なデータの徹底的な分析を通じて、強度変調放射線治療市場における投資評価の実行可能性について、市場リーダー/新規参入者/小規模企業の助けとなり、それによって強固なリスク評価が容易になり、十分な情報に基づいた投資決定が可能になります。用途、エンドユーザー、地域などの詳細な市場区分により、的確なセグメントターゲティングのためのテーラーメイドの洞察が得られます。また、極めて重要なトレンド、成長触媒、課題、展望を網羅的に評価し、鋭い洞察力で戦略的意思決定を後押しします。
本レポートは、以下のポイントに関する洞察を提供しています：
- 強度変調放射線治療市場の成長に影響を与える主要な促進要因（がん患者人口の増加、がん管理に対する政府の取り組みの増加、放射線治療による非侵襲的治療の進歩）、阻害要因（熟練した放射線科医/腫瘍医の不足、画像誘導放射線治療による治療費の高騰、治療のための画像技術の複雑さ）、機会（新興国における主要企業の拡大、発展途上国における医療費の増加）、課題（代替技術の利用可能性）に関する分析を掲載しています。
- 製品開発/イノベーション：画像誘導放射線治療市場における今後の技術、研究開発活動、新製品・サービス開始に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、様々な地域における強度変調放射線治療市場を分析しています。
- 市場の多様化：強度変調放射線治療市場における新製品、未開拓地域、最近の開発、投資に関する詳細情報
- 競争力の評価：Siemens Healthineers AG（ドイツ）、Elekta（スウェーデン）、Accuray Incorporated（米国）などの主要企業の市場シェア、成長戦略、サービス内容などを詳細に評価。

ページTOPに戻る


目次

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 22
1.3 STUDY SCOPE 23
1.3.1 MARKET SCOPE 23
1.3.2 REGIONAL SCOPE 23
1.3.3 YEARS CONSIDERED 24
1.3.4 CURRENCY CONSIDERED 24
1.4 RESEARCH LIMITATIONS 24
1.5 STAKEHOLDERS 24
1.6 RECESSION IMPACT: INTENSITY-MODULATED RADIATION THERAPY MARKET 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN 26
2.1.1 SECONDARY RESEARCH 27
2.1.2 PRIMARY RESEARCH 28
2.1.2.1 Primary sources 28
FIGURE 2 KEY DATA FROM SECONDARY SOURCES 29
2.1.2.2 Breakdown of primary sources 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 BOTTOM-UP APPROACH 31
2.2.1.1 Company revenue estimation 32
FIGURE 6 COMPANY REVENUE ESTIMATION: INTENSITY-MODULATED RADIATION THERAPY MARKET 32
2.2.1.2 Customer-based market estimation 32
FIGURE 7 BOTTOM-UP APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 33
2.2.2 TOP-DOWN APPROACH 33
2.2.3 PRIMARY INTERVIEWS 33
FIGURE 8 TOP-DOWN APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 34
2.3 MARKET ESTIMATION AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.4 MARKET SHARE ASSESSMENT 36
2.5 ASSUMPTIONS 37
2.5.1 STUDY ASSUMPTIONS 37
2.5.2 ASSUMPTIONS FOR GROWTH FORECAST MODEL 37
2.6 RISK ASSESSMENT 37
2.7 IMPACT OF RECESSION ON INTENSITY-MODULATED RADIATION THERAPY MARKET 38
3 EXECUTIVE SUMMARY 40
FIGURE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2023 VS. 2028 (USD MILLION) 40
FIGURE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 41
FIGURE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 41
FIGURE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY REGION, 2022 42
4 PREMIUM INSIGHTS 43
4.1 INTENSITY-MODULATED RADIATION THERAPY MARKET OVERVIEW 43
FIGURE 14 INCREASING PREVALENCE OF CANCER AND GROWING GERIATRIC POPULATION TO DRIVE MARKET 43
4.2 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE AND COUNTRY 44
FIGURE 15 PHOTON RADIATION AND US COMMANDED LARGEST MARKET SHARE IN 2022 44
4.3 REGIONAL SNAPSHOT OF INTENSITY-MODULATED RADIATION THERAPY MARKET 45
FIGURE 16 MIDDLE EAST & AFRICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INTENSITY-MODULATED RADIATION THERAPY MARKET 46
5.2.1 DRIVERS 47
5.2.1.1 Rising prevalence of chronic diseases among all age groups 47
FIGURE 18 NEW CANCER CASES GLOBALLY, 2020 47
5.2.1.2 Advancements in radiation therapy technologies to improve treatment and reduce side effects 47
5.2.1.3 Improved patient outcomes and potential cost savings in long run 48
5.2.1.4 Reduced infection risk and shorter recovery periods with minimal scarring 48
5.2.2 RESTRAINTS 49
5.2.2.1 Dearth of skilled radiologists/oncologists for operating automated radiotherapy equipment 49
5.2.2.2 High cost of intensity-modulated radiation therapy systems 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Rapid economic development and rising healthcare expenditure across emerging economies 50
5.2.3.2 Growing government and private investments in cancer treatment 50
5.2.3.3 Increased adoption of radiation therapy as primary treatment option for cancer 51
5.2.4 CHALLENGES 52
5.2.4.1 Increased risk of radiation exposure for both patients and healthcare staff 52
5.2.4.2 Increased competition from alternative treatment modalities 52
5.3 KEY STAKEHOLDERS AND BUYING CRITERIA 53
5.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 53
TABLE 1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INTENSITY-MODULATED RADIATION THERAPY PRODUCTS 53
5.4 PORTER’S FIVE FORCES ANALYSIS 53
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 53
5.4.1 THREAT OF NEW ENTRANTS 54
5.4.2 THREAT OF SUBSTITUTES 54
5.4.3 BARGAINING POWER OF SUPPLIERS 54
5.4.4 BARGAINING POWER OF BUYERS 54
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.5 REGULATORY ANALYSIS 55
5.5.1 US 55
TABLE 3 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 56
5.5.2 EUROPEAN COUNTRIES 56
5.5.3 JAPAN 56
TABLE 4 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 57
5.6 REIMBURSEMENT SCENARIO ANALYSIS 57
TABLE 5 CPT CODES FOR MAJOR INTENSITY-MODULATED RADIATION THERAPY PROCEDURES 57
TABLE 6 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 58
5.7 ECOSYSTEM MARKET MAP 59
FIGURE 19 ECOSYSTEM MARKET MAP: INTENSITY-MODULATED RADIATION THERAPY MARKET 59
5.8 VALUE CHAIN ANALYSIS 59
5.8.1 TECHNOLOGY INNOVATION 60
5.8.2 PROCUREMENT AND PRODUCT DESIGN 60
5.8.3 MARKETING, SALES, AND DISTRIBUTION AND POST-SALES SERVICES 60
FIGURE 20 VALUE CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 60
5.9 SUPPLY CHAIN ANALYSIS 61
5.9.1 PROMINENT COMPANIES 61
5.9.2 SMALL & MEDIUM-SIZED COMPANIES 61
5.9.3 END USERS 61
FIGURE 21 SUPPLY CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 61
5.10 PRICING ANALYSIS 62
5.11 PATENT ANALYSIS 62
FIGURE 22 TOP 10 PATENT APPLICANTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 62
FIGURE 23 TOP 10 PATENT OWNERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 63
5.12 TECHNOLOGY ANALYSIS 63
TABLE 7 IMPORTANT PRODUCT LAUNCHES IN INTENSITY-MODULATED RADIATION THERAPY MARKET (JANUARY 2015–JUNE 2022) 63
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 64
TABLE 8 DETAILED LIST OF KEY CONFERENCES AND EVENTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2023–2024) 64
6 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION 65
6.1 INTRODUCTION 66
TABLE 9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 66
6.2 PROSTATE CANCER 66
6.2.1 ADVANCEMENTS IN NONINVASIVE RADIATION THERAPY TECHNOLOGY TO DRIVE MARKET 66
TABLE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 67
6.3 BREAST CANCER 67
6.3.1 LIFESTYLE CHANGES AND FOCUS ON EARLY DETECTION THROUGH SCREENING PROGRAMS TO DRIVE MARKET 67
TABLE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 68
6.4 LUNG CANCER 68
6.4.1 INCREASING RESEARCH AND CLINICAL TRIAL ACTIVITY TO DRIVE MARKET 68
TABLE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.5 GASTROINTESTINAL CANCER 69
6.5.1 RISING CONSUMPTION OF SALT-PRESERVED FOOD AND ALCOHOL TO DRIVE MARKET 69
TABLE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.6 BRAIN CANCER 70
6.6.1 NEGLIGENCE IN PRE-SCREENING PROCEDURES TO LIMIT MARKET 70
TABLE 14 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BRAIN CANCER, BY REGION, 2021–2028 (USD MILLION) 70
6.7 OTHER CANCERS 70
TABLE 15 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 71
7 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE 72
7.1 INTRODUCTION 73
TABLE 16 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 73
7.2 PHOTON RADIATION 73
7.2.1 RISING CANCER CASES GLOBALLY TO DRIVE MARKET 73
TABLE 17 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PHOTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.3 ELECTRON RADIATION 74
7.3.1 TECHNIQUE LIMITATIONS AND REDUCED TREATMENT EFFECTIVENESS TO LIMIT ADOPTION 74
TABLE 18 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR ELECTRON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.4 PROTON RADIATION 75
7.4.1 EASY, PRECISE DOSAGE DELIVERY TO CANCEROUS TISSUES TO DRIVE USAGE 75
TABLE 19 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 75
7.5 CARBON-ION RADIATION 76
7.5.1 NEED FOR SPECIALIZED FACILITIES AND TREATMENT ROOMS FOR HEAVY ION-BASED THERAPIES TO LIMIT MARKET 76
TABLE 20 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR CARBON-ION RADIATION, BY REGION, 2021–2028 (USD MILLION) 76
8 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER 77
8.1 INTRODUCTION 78
TABLE 21 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 78
8.2 HOSPITALS 78
8.2.1 RAPID ADOPTION OF INVASIVE TECHNOLOGIES AND INCREASED NUMBER OF CANCER PATIENTS TO DRIVE MARKET 78
TABLE 22 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 79
8.3 INDEPENDENT RADIOTHERAPY CENTERS 79
8.3.1 LOWER OVERHEAD COSTS AND SHORTER WAITING PERIOD TO DRIVE MARKET 79
TABLE 23 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2021–2028 (USD MILLION) 80
9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION 81
9.1 INTRODUCTION 82
TABLE 24 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 82
9.2 NORTH AMERICA 83
FIGURE 24 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 83
TABLE 25 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 26 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 84
TABLE 27 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 85
9.2.1 NORTH AMERICA: RECESSION IMPACT 85
9.2.2 US 86
9.2.2.1 US dominated North American intensity-modulated radiation therapy market in 2022 86
TABLE 29 US: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 86
9.2.3 CANADA 86
9.2.3.1 Increasing prevalence of cancer and high demand for timely diagnosis to drive market 86
TABLE 30 CANADA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 87
9.3 EUROPE 87
TABLE 31 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 32 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 88
TABLE 33 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
TABLE 34 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 89
9.3.1 EUROPE: RECESSION IMPACT 89
9.3.2 GERMANY 89
9.3.2.1 Increasing geriatric population and rising life expectancy to drive market 89
TABLE 35 GERMANY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.3 FRANCE 90
9.3.3.1 Increasing government initiatives for better healthcare practices to drive market 90
TABLE 36 FRANCE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.4 UK 91
9.3.4.1 High burden of cancer and rising preference for noninvasive cancer management to drive market 91
TABLE 37 UK: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 91
9.3.5 ITALY 91
9.3.5.1 Increasing geriatric population and rising use of noninvasive cancer treatment methods to drive market 91
TABLE 38 ITALY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.6 SPAIN 92
9.3.6.1 Increasing technological developments in healthcare to drive market 92
TABLE 39 SPAIN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.7 REST OF EUROPE 93
TABLE 40 REST OF EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 93
9.4 ASIA PACIFIC 93
FIGURE 25 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 94
TABLE 41 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 42 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 95
TABLE 43 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
TABLE 44 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.4.1 ASIA PACIFIC: RECESSION IMPACT 96
9.4.2 JAPAN 97
9.4.2.1 Increased geriatric population and presence of well-established healthcare sector to drive market 97
TABLE 45 JAPAN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 97
9.4.3 CHINA 98
9.4.3.1 Growing prevalence of cancer and developing healthcare infrastructure to drive market 98
TABLE 46 CHINA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 98
9.4.4 INDIA 99
9.4.4.1 Increasing target patient population and rising availability of advanced surgical treatments to drive market 99
TABLE 47 INDIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 99
9.4.5 AUSTRALIA 99
9.4.5.1 Developing healthcare sector with increasing availability of advanced surgical and imaging procedures to drive market 99
TABLE 48 AUSTRALIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.6 SOUTH KOREA 100
9.4.6.1 Growing target cancer patient population and increasing awareness of early cancer diagnosis to drive market 100
TABLE 49 SOUTH KOREA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.7 REST OF ASIA PACIFIC 101
TABLE 50 REST OF ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 101
9.5 LATIN AMERICA 101
TABLE 51 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 52 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 102
TABLE 53 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 54 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.5.1 LATIN AMERICA: RECESSION IMPACT 103
9.5.2 BRAZIL 104
9.5.2.1 Developing healthcare sector and increasing availability of advanced surgical treatments to drive market 104
TABLE 55 BRAZIL: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 104
9.5.3 MEXICO 104
9.5.3.1 Favorable government initiatives and low-cost manufacturing advantages to drive market 104
TABLE 56 MEXICO: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.5.4 REST OF LATIN AMERICA 105
TABLE 57 REST OF LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.6 MIDDLE EAST & AFRICA 106
9.6.1 FAVORABLE GOVERNMENT INITIATIVES AND ECONOMIC GROWTH TO DRIVE MARKET 106
TABLE 58 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 106
TABLE 59 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 60 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 107
10 COMPETITIVE LANDSCAPE 108
10.1 OVERVIEW 108
10.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 108
FIGURE 26 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2019–2023) 109
10.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 110
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2019–2022) 110
10.4 MARKET SHARE ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY KEY PLAYER (2022) 110
FIGURE 28 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY KEY PLAYER, 2022 110
10.5 COMPANY EVALUATION MATRIX FOR PLAYERS (2022) 111
10.5.1 STARS 111
10.5.2 PERVASIVE PLAYERS 111
10.5.3 EMERGING LEADERS 111
10.5.4 PARTICIPANTS 111
FIGURE 29 COMPANY EVALUATION MATRIX FOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET, 2022 112
10.6 COMPETITIVE BENCHMARKING 113
10.6.1 OVERALL COMPANY FOOTPRINT 113
TABLE 61 OVERALL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.2 PRODUCT FOOTPRINT 113
TABLE 62 PRODUCT FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.3 REGIONAL FOOTPRINT 114
TABLE 63 REGIONAL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 114
10.7 COMPETITIVE SCENARIOS AND TRENDS (2020–2023) 115
10.7.1 KEY PRODUCT LAUNCHES AND APPROVALS 115
TABLE 64 KEY PRODUCT LAUNCHES AND APPROVALS 115
10.7.2 KEY DEALS 116
TABLE 65 KEY DEALS 116
10.7.3 OTHER KEY DEVELOPMENTS 117
TABLE 66 OTHER KEY DEVELOPMENTS 117
11 COMPANY PROFILES 118
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
11.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 118
TABLE 67 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 118
FIGURE 30 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 119
11.2 ELEKTA 126
TABLE 68 ELEKTA: COMPANY OVERVIEW 126
FIGURE 31 ELEKTA: COMPANY SNAPSHOT (2022) 127
11.3 ACCURAY INCORPORATED 132
TABLE 69 ACCURAY INCORPORATED: COMPANY OVERVIEW 132
FIGURE 32 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022) 133
11.4 IBA WORLDWIDE 137
TABLE 70 IBA WORLDWIDE: COMPANY OVERVIEW 137
FIGURE 33 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 138
11.5 HITACHI, LTD. 141
TABLE 71 HITACHI, LTD.: COMPANY OVERVIEW 141
FIGURE 34 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 142
11.6 MEVION MEDICAL SYSTEMS 144
TABLE 72 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 144
11.7 KONINKLIJKE PHILIPS N.V. 147
TABLE 73 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 147
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 148
11.8 RAYSEARCH LABORATORIES 150
TABLE 74 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 150
FIGURE 36 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022) 151
11.9 BRAINLAB AG 154
TABLE 75 BRAINLAB AG: COMPANY OVERVIEW 154
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX 155
12.1 DISCUSSION GUIDE 155
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 160
12.3 CUSTOMIZATION OPTIONS 162
12.4 RELATED REPORTS 162
12.5 AUTHOR DETAILS 163

　

ページTOPに戻る


　

Summary

The global intensity-modulated radiotherapy market is projected to reach USD 2.8 billion by 2028 from USD 2.2 billion in 2023, growing at a CAGR of 5.2% during the forecast period. The projected surge in market growth for the Intensity-modulated radiotherapy market (IMRT) is underpinned by a confluence of compelling advantages. Notably, IMRT ‘capacity to achieve exceptional precision in tumor targeting, coupled with its ability to mitigate collateral damage to healthy tissues, stands as a pivotal driver. Furthermore, the escalating global incidence of cancer amplifies the demand for advanced treatment modalities, with IMRT positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of IMRT adoption in the forthcoming forecasting years.

“The Brain cancer application segment to register highest CAGR over the forecast period of 2023-2027”
Based on the application, the Intensity-modulated radiotherapy market is segmented into prostate cancer, lung cancer, head & neck cancer, breast cancer, gastrointestinal cancer, gynecological cancer, and other applications. The Breast cancer segment is witnessed the highest growth rate In 2022. The increase in breast cancer can be seen due to aging factors, genetic factors like - inherited genetic mutations, such as BRCA1 and BRCA2, contribute to a small percentage of breast cancer cases, the use of hormone replacement therapy can be a few of the potential factors increasing the rate of breast cancers. The incidence of breast cancer may appear to be increasing, but breast cancer mortality rates have been declining due to earlier detection and advances in treatment. IMRT allows physicians and patients to eradicate the cells efficiently by using proper radiation intensity .

“Hospitals’ segment to register for the largest market share of the Intensity-modulated radiotherapy market 2022-2027”
The major end users in the Intensity-modulated radiotherapy market are hospitals. The hospitals end-user segment is estimated to hold a significant market share of the Intensity-modulated radiotherapy market during the forecast period. Hospitals, characterized by their capacity to provide a comprehensive array of medical services within a singular facility, confer a distinctive convenience to patients undergoing the Intensity-modulated radiotherapy market (IMRT). This convenience stems from the consolidation of diverse medical needs under one roof, thereby mitigating the necessity for patients to seek multiple appointments at disparate venues. This strategic amalgamation of services not only streamlines patient care but also augments the attractiveness of IMRT as a preferred treatment option. As a result, this seamless alignment of convenience and comprehensive care significantly contributes to the advancement and prominence of the Intensity-modulated radiotherapy market within hospital settings.
Technological Advances: Hospitals frequently maintain cutting-edge infrastructure and technological capabilities essential for the successful integration of the Intensity-modulated radiotherapy market (IMRT), thus assuring the ready availability of requisite resources. This pivotal attribute distinctly contributes to the advancement and fortification of the image-guided radiation therapy market.

“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for image-guided radiation therapy. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Intensity-modulated radiotherapy market (IMRT) substantiates its pivotal role in enhancing the market landscape.
The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Intensity-modulated radiotherapy market (IMRT), confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region's desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of IMRT.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in this market are Varian Medical Systems, Inc., Elekta (Sweden), and Accuray Incorporated (US), Hitachi (Japan) among others.

Research Coverage

• The report studies the Intensity-modulated radiotherapy market based on radiation type, application, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Intensity-modulated radiotherapy market
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Intensity-modulated radiotherapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing prevalence of cancer patient population, Increasing government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of image-guided radiation therapy treatment, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Intensity-modulated radiotherapy market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the image-guided radiation therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Intensity-modulated radiotherapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Intensity-modulated radiotherapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 22
1.3 STUDY SCOPE 23
1.3.1 MARKET SCOPE 23
1.3.2 REGIONAL SCOPE 23
1.3.3 YEARS CONSIDERED 24
1.3.4 CURRENCY CONSIDERED 24
1.4 RESEARCH LIMITATIONS 24
1.5 STAKEHOLDERS 24
1.6 RECESSION IMPACT: INTENSITY-MODULATED RADIATION THERAPY MARKET 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN 26
2.1.1 SECONDARY RESEARCH 27
2.1.2 PRIMARY RESEARCH 28
2.1.2.1 Primary sources 28
FIGURE 2 KEY DATA FROM SECONDARY SOURCES 29
2.1.2.2 Breakdown of primary sources 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 BOTTOM-UP APPROACH 31
2.2.1.1 Company revenue estimation 32
FIGURE 6 COMPANY REVENUE ESTIMATION: INTENSITY-MODULATED RADIATION THERAPY MARKET 32
2.2.1.2 Customer-based market estimation 32
FIGURE 7 BOTTOM-UP APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 33
2.2.2 TOP-DOWN APPROACH 33
2.2.3 PRIMARY INTERVIEWS 33
FIGURE 8 TOP-DOWN APPROACH: INTENSITY-MODULATED RADIATION THERAPY MARKET 34
2.3 MARKET ESTIMATION AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.4 MARKET SHARE ASSESSMENT 36
2.5 ASSUMPTIONS 37
2.5.1 STUDY ASSUMPTIONS 37
2.5.2 ASSUMPTIONS FOR GROWTH FORECAST MODEL 37
2.6 RISK ASSESSMENT 37
2.7 IMPACT OF RECESSION ON INTENSITY-MODULATED RADIATION THERAPY MARKET 38
3 EXECUTIVE SUMMARY 40
FIGURE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2023 VS. 2028 (USD MILLION) 40
FIGURE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 41
FIGURE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 41
FIGURE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY REGION, 2022 42
4 PREMIUM INSIGHTS 43
4.1 INTENSITY-MODULATED RADIATION THERAPY MARKET OVERVIEW 43
FIGURE 14 INCREASING PREVALENCE OF CANCER AND GROWING GERIATRIC POPULATION TO DRIVE MARKET 43
4.2 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE AND COUNTRY 44
FIGURE 15 PHOTON RADIATION AND US COMMANDED LARGEST MARKET SHARE IN 2022 44
4.3 REGIONAL SNAPSHOT OF INTENSITY-MODULATED RADIATION THERAPY MARKET 45
FIGURE 16 MIDDLE EAST & AFRICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INTENSITY-MODULATED RADIATION THERAPY MARKET 46
5.2.1 DRIVERS 47
5.2.1.1 Rising prevalence of chronic diseases among all age groups 47
FIGURE 18 NEW CANCER CASES GLOBALLY, 2020 47
5.2.1.2 Advancements in radiation therapy technologies to improve treatment and reduce side effects 47
5.2.1.3 Improved patient outcomes and potential cost savings in long run 48
5.2.1.4 Reduced infection risk and shorter recovery periods with minimal scarring 48
5.2.2 RESTRAINTS 49
5.2.2.1 Dearth of skilled radiologists/oncologists for operating automated radiotherapy equipment 49
5.2.2.2 High cost of intensity-modulated radiation therapy systems 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Rapid economic development and rising healthcare expenditure across emerging economies 50
5.2.3.2 Growing government and private investments in cancer treatment 50
5.2.3.3 Increased adoption of radiation therapy as primary treatment option for cancer 51
5.2.4 CHALLENGES 52
5.2.4.1 Increased risk of radiation exposure for both patients and healthcare staff 52
5.2.4.2 Increased competition from alternative treatment modalities 52
5.3 KEY STAKEHOLDERS AND BUYING CRITERIA 53
5.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 53
TABLE 1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INTENSITY-MODULATED RADIATION THERAPY PRODUCTS 53
5.4 PORTER’S FIVE FORCES ANALYSIS 53
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 53
5.4.1 THREAT OF NEW ENTRANTS 54
5.4.2 THREAT OF SUBSTITUTES 54
5.4.3 BARGAINING POWER OF SUPPLIERS 54
5.4.4 BARGAINING POWER OF BUYERS 54
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.5 REGULATORY ANALYSIS 55
5.5.1 US 55
TABLE 3 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 56
5.5.2 EUROPEAN COUNTRIES 56
5.5.3 JAPAN 56
TABLE 4 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 57
5.6 REIMBURSEMENT SCENARIO ANALYSIS 57
TABLE 5 CPT CODES FOR MAJOR INTENSITY-MODULATED RADIATION THERAPY PROCEDURES 57
TABLE 6 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022 58
5.7 ECOSYSTEM MARKET MAP 59
FIGURE 19 ECOSYSTEM MARKET MAP: INTENSITY-MODULATED RADIATION THERAPY MARKET 59
5.8 VALUE CHAIN ANALYSIS 59
5.8.1 TECHNOLOGY INNOVATION 60
5.8.2 PROCUREMENT AND PRODUCT DESIGN 60
5.8.3 MARKETING, SALES, AND DISTRIBUTION AND POST-SALES SERVICES 60
FIGURE 20 VALUE CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 60
5.9 SUPPLY CHAIN ANALYSIS 61
5.9.1 PROMINENT COMPANIES 61
5.9.2 SMALL & MEDIUM-SIZED COMPANIES 61
5.9.3 END USERS 61
FIGURE 21 SUPPLY CHAIN ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 61
5.10 PRICING ANALYSIS 62
5.11 PATENT ANALYSIS 62
FIGURE 22 TOP 10 PATENT APPLICANTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 62
FIGURE 23 TOP 10 PATENT OWNERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 63
5.12 TECHNOLOGY ANALYSIS 63
TABLE 7 IMPORTANT PRODUCT LAUNCHES IN INTENSITY-MODULATED RADIATION THERAPY MARKET (JANUARY 2015–JUNE 2022) 63
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 64
TABLE 8 DETAILED LIST OF KEY CONFERENCES AND EVENTS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2023–2024) 64
6 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION 65
6.1 INTRODUCTION 66
TABLE 9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 66
6.2 PROSTATE CANCER 66
6.2.1 ADVANCEMENTS IN NONINVASIVE RADIATION THERAPY TECHNOLOGY TO DRIVE MARKET 66
TABLE 10 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 67
6.3 BREAST CANCER 67
6.3.1 LIFESTYLE CHANGES AND FOCUS ON EARLY DETECTION THROUGH SCREENING PROGRAMS TO DRIVE MARKET 67
TABLE 11 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 68
6.4 LUNG CANCER 68
6.4.1 INCREASING RESEARCH AND CLINICAL TRIAL ACTIVITY TO DRIVE MARKET 68
TABLE 12 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.5 GASTROINTESTINAL CANCER 69
6.5.1 RISING CONSUMPTION OF SALT-PRESERVED FOOD AND ALCOHOL TO DRIVE MARKET 69
TABLE 13 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2021–2028 (USD MILLION) 69
6.6 BRAIN CANCER 70
6.6.1 NEGLIGENCE IN PRE-SCREENING PROCEDURES TO LIMIT MARKET 70
TABLE 14 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR BRAIN CANCER, BY REGION, 2021–2028 (USD MILLION) 70
6.7 OTHER CANCERS 70
TABLE 15 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 71
7 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE 72
7.1 INTRODUCTION 73
TABLE 16 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 73
7.2 PHOTON RADIATION 73
7.2.1 RISING CANCER CASES GLOBALLY TO DRIVE MARKET 73
TABLE 17 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PHOTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.3 ELECTRON RADIATION 74
7.3.1 TECHNIQUE LIMITATIONS AND REDUCED TREATMENT EFFECTIVENESS TO LIMIT ADOPTION 74
TABLE 18 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR ELECTRON RADIATION, BY REGION, 2021–2028 (USD MILLION) 74
7.4 PROTON RADIATION 75
7.4.1 EASY, PRECISE DOSAGE DELIVERY TO CANCEROUS TISSUES TO DRIVE USAGE 75
TABLE 19 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR PROTON RADIATION, BY REGION, 2021–2028 (USD MILLION) 75
7.5 CARBON-ION RADIATION 76
7.5.1 NEED FOR SPECIALIZED FACILITIES AND TREATMENT ROOMS FOR HEAVY ION-BASED THERAPIES TO LIMIT MARKET 76
TABLE 20 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR CARBON-ION RADIATION, BY REGION, 2021–2028 (USD MILLION) 76
8 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER 77
8.1 INTRODUCTION 78
TABLE 21 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 78
8.2 HOSPITALS 78
8.2.1 RAPID ADOPTION OF INVASIVE TECHNOLOGIES AND INCREASED NUMBER OF CANCER PATIENTS TO DRIVE MARKET 78
TABLE 22 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 79
8.3 INDEPENDENT RADIOTHERAPY CENTERS 79
8.3.1 LOWER OVERHEAD COSTS AND SHORTER WAITING PERIOD TO DRIVE MARKET 79
TABLE 23 INTENSITY-MODULATED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2021–2028 (USD MILLION) 80
9 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION 81
9.1 INTRODUCTION 82
TABLE 24 INTENSITY-MODULATED RADIATION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 82
9.2 NORTH AMERICA 83
FIGURE 24 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 83
TABLE 25 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 26 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 84
TABLE 27 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 85
TABLE 28 NORTH AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 85
9.2.1 NORTH AMERICA: RECESSION IMPACT 85
9.2.2 US 86
9.2.2.1 US dominated North American intensity-modulated radiation therapy market in 2022 86
TABLE 29 US: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 86
9.2.3 CANADA 86
9.2.3.1 Increasing prevalence of cancer and high demand for timely diagnosis to drive market 86
TABLE 30 CANADA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 87
9.3 EUROPE 87
TABLE 31 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 32 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 88
TABLE 33 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
TABLE 34 EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 89
9.3.1 EUROPE: RECESSION IMPACT 89
9.3.2 GERMANY 89
9.3.2.1 Increasing geriatric population and rising life expectancy to drive market 89
TABLE 35 GERMANY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.3 FRANCE 90
9.3.3.1 Increasing government initiatives for better healthcare practices to drive market 90
TABLE 36 FRANCE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 90
9.3.4 UK 91
9.3.4.1 High burden of cancer and rising preference for noninvasive cancer management to drive market 91
TABLE 37 UK: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 91
9.3.5 ITALY 91
9.3.5.1 Increasing geriatric population and rising use of noninvasive cancer treatment methods to drive market 91
TABLE 38 ITALY: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.6 SPAIN 92
9.3.6.1 Increasing technological developments in healthcare to drive market 92
TABLE 39 SPAIN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 92
9.3.7 REST OF EUROPE 93
TABLE 40 REST OF EUROPE: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 93
9.4 ASIA PACIFIC 93
FIGURE 25 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET SNAPSHOT 94
TABLE 41 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 42 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 95
TABLE 43 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
TABLE 44 ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 96
9.4.1 ASIA PACIFIC: RECESSION IMPACT 96
9.4.2 JAPAN 97
9.4.2.1 Increased geriatric population and presence of well-established healthcare sector to drive market 97
TABLE 45 JAPAN: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 97
9.4.3 CHINA 98
9.4.3.1 Growing prevalence of cancer and developing healthcare infrastructure to drive market 98
TABLE 46 CHINA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 98
9.4.4 INDIA 99
9.4.4.1 Increasing target patient population and rising availability of advanced surgical treatments to drive market 99
TABLE 47 INDIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 99
9.4.5 AUSTRALIA 99
9.4.5.1 Developing healthcare sector with increasing availability of advanced surgical and imaging procedures to drive market 99
TABLE 48 AUSTRALIA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.6 SOUTH KOREA 100
9.4.6.1 Growing target cancer patient population and increasing awareness of early cancer diagnosis to drive market 100
TABLE 49 SOUTH KOREA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 100
9.4.7 REST OF ASIA PACIFIC 101
TABLE 50 REST OF ASIA PACIFIC: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 101
9.5 LATIN AMERICA 101
TABLE 51 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 52 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 102
TABLE 53 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 54 LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.5.1 LATIN AMERICA: RECESSION IMPACT 103
9.5.2 BRAZIL 104
9.5.2.1 Developing healthcare sector and increasing availability of advanced surgical treatments to drive market 104
TABLE 55 BRAZIL: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 104
9.5.3 MEXICO 104
9.5.3.1 Favorable government initiatives and low-cost manufacturing advantages to drive market 104
TABLE 56 MEXICO: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.5.4 REST OF LATIN AMERICA 105
TABLE 57 REST OF LATIN AMERICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 105
9.6 MIDDLE EAST & AFRICA 106
9.6.1 FAVORABLE GOVERNMENT INITIATIVES AND ECONOMIC GROWTH TO DRIVE MARKET 106
TABLE 58 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY RADIATION TYPE, 2021–2028 (USD MILLION) 106
TABLE 59 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 60 MIDDLE EAST & AFRICA: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 107
10 COMPETITIVE LANDSCAPE 108
10.1 OVERVIEW 108
10.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET 108
FIGURE 26 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET (2019–2023) 109
10.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 110
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2019–2022) 110
10.4 MARKET SHARE ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET, BY KEY PLAYER (2022) 110
FIGURE 28 INTENSITY-MODULATED RADIATION THERAPY MARKET SHARE, BY KEY PLAYER, 2022 110
10.5 COMPANY EVALUATION MATRIX FOR PLAYERS (2022) 111
10.5.1 STARS 111
10.5.2 PERVASIVE PLAYERS 111
10.5.3 EMERGING LEADERS 111
10.5.4 PARTICIPANTS 111
FIGURE 29 COMPANY EVALUATION MATRIX FOR PLAYERS IN INTENSITY-MODULATED RADIATION THERAPY MARKET, 2022 112
10.6 COMPETITIVE BENCHMARKING 113
10.6.1 OVERALL COMPANY FOOTPRINT 113
TABLE 61 OVERALL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.2 PRODUCT FOOTPRINT 113
TABLE 62 PRODUCT FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 113
10.6.3 REGIONAL FOOTPRINT 114
TABLE 63 REGIONAL FOOTPRINT ANALYSIS: INTENSITY-MODULATED RADIATION THERAPY MARKET 114
10.7 COMPETITIVE SCENARIOS AND TRENDS (2020–2023) 115
10.7.1 KEY PRODUCT LAUNCHES AND APPROVALS 115
TABLE 64 KEY PRODUCT LAUNCHES AND APPROVALS 115
10.7.2 KEY DEALS 116
TABLE 65 KEY DEALS 116
10.7.3 OTHER KEY DEVELOPMENTS 117
TABLE 66 OTHER KEY DEVELOPMENTS 117
11 COMPANY PROFILES 118
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
11.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 118
TABLE 67 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 118
FIGURE 30 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 119
11.2 ELEKTA 126
TABLE 68 ELEKTA: COMPANY OVERVIEW 126
FIGURE 31 ELEKTA: COMPANY SNAPSHOT (2022) 127
11.3 ACCURAY INCORPORATED 132
TABLE 69 ACCURAY INCORPORATED: COMPANY OVERVIEW 132
FIGURE 32 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2022) 133
11.4 IBA WORLDWIDE 137
TABLE 70 IBA WORLDWIDE: COMPANY OVERVIEW 137
FIGURE 33 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 138
11.5 HITACHI, LTD. 141
TABLE 71 HITACHI, LTD.: COMPANY OVERVIEW 141
FIGURE 34 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 142
11.6 MEVION MEDICAL SYSTEMS 144
TABLE 72 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 144
11.7 KONINKLIJKE PHILIPS N.V. 147
TABLE 73 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 147
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 148
11.8 RAYSEARCH LABORATORIES 150
TABLE 74 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 150
FIGURE 36 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022) 151
11.9 BRAINLAB AG 154
TABLE 75 BRAINLAB AG: COMPANY OVERVIEW 154
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX 155
12.1 DISCUSSION GUIDE 155
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 160
12.3 CUSTOMIZATION OPTIONS 162
12.4 RELATED REPORTS 162
12.5 AUTHOR DETAILS 163

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（hospitals）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20　10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.